Ka morao
Liphekolo tse thehiloeng ho Incretin ke khale li tsejoa hore li ntlafatsa ka bobelitaolo ea tsoekere ea malilephokotso ya boima ba mmele. Lithethefatsi tse tloaelehileng tsa incretin li lebisa tlhokomelo hoGLP-1 receptor, haTirzepatidee emela moloko o mocha oa "twincretin” liakhente - ho sebetsaGIP ka bobeli (insulinotropic polypeptide e itšetlehileng ka tsoekere)leGLP-1li-receptors.
Ketso ena e habeli e bonts'itsoe ho ntlafatsa melemo ea metabolic le ho khothaletsa tahlehelo e kholo ea boima ba 'mele ha e bapisoa le li-agonists tsa GLP-1 feela.
Moralo oa Boithuto oa SURMOUNT-1
MOHATO-1e ne e le ateko ea bongaka e sa reroang, e sa boneng habeli, mohato oa 3e tsamaisitsoe libakeng tse 119 linaheng tse robong.
Barupeluoa ba ne ba kenyelletsa batho ba baholo bao e neng e le:
- Botenya(BMI ≥30), kapa
- Boima bo feteletseng(BMI ≥ 27) e nang le bonyane lefu le le leng le amanang le boima ba 'mele (mohlala, khatello ea mali, dyslipidemia, ho koaleha moea ka nakoana borokong, kapa lefu la pelo).
Batho ba nang le lefu la tsoekere, tšebeliso ea morao-rao ea lithethefatsi tsa ho theola boima ba 'mele, kapa opereishene ea pele ea bariatric ba ile ba qheleloa ka thoko.
Barupeluoa ba ile ba abeloa ho fumana liente tsa hang ka beke tsa:
- Tirzepatide 5 mg, 10 mg, 15 mg, kapa
- Sebaka
Barupeluoa bohle ba boetse ba fumane tataiso ea mokhoa oa bophelo:
- A khaello ea khalori ea 500 kcal / letsatsi
- BonyaneMetsotso e 150 ea boikoetliso ba 'mele ka beke
Kalafo e ile ea tšoarellaLibeke tse 72, ho akarelletsa le aMokhahlelo oa ho nyolla lethal dose ea libeke tse 20e lateloa ke nako ea tlhokomelo ea libeke tse 52.
Liphetho Overview
Kakaretso ea2,359 barupeluoaba ngolisitsoe.
Karolelano ea lilemo e ne e lelilemo tse 44.9, 67.5% e ne e le basali, ka boikhohomosoboima ba 'mele ke 104.8 lik'hilogramaleBMI ea 38.0.
Ho fokotsa boima ba 'mele ka beke ea 72
| Sehlopha sa litekanyetso | % Phetoho ea Boima | Ho Fetola Boima bo Bobebe (kg) | Tahlehelo e Eketsehileng vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | -16.1 lik'hilograma | -13.5% |
| 10 mg | -19.5% | -22.2 lik'hilograma | -18.9% |
| 15 mg | -20.9% | -23.6 lik'hilograma | -20.1% |
| Sebaka | -3.1% | -2,4 lik'hilograma | - |
Tirzepatide e fihletse 15-21% e bolela ho fokotsa boima ba 'mele, e bontšang liphello tse hlakileng tse itšetlehileng ka lethal dose.
Peresente ea Barupeluoa ba Finyellang Tahlehelo ea Boima ba Boima
| Ho theola boima ba 'mele (%) | 5 mg | 10 mg | 15 mg | Sebaka |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Ho feta halofoea barupeluoa ba amohelang≥10 mgTirzepatide e fihlile≥20% tahlehelo ea boima ba 'mele, e atamela phello e bonoang ka ho buuoa ka bariatric.
Melemo ea Metabolic le Cardiovascular
Ha ho bapisoa le placebo, Tirzepatide e ntlafetse haholo:
- Sedikadikwe sa letheka
- Khatello ea mali ea systolic
- Boemo ba lipid
- Ho potlakisa maemo a insulin
Har'a barupeluoa ba nang leprediabetes, 95.3% e khutletse maemong a tloaelehileng a tsoekere, ha ho bapisoa le61.9%sehlopheng sa placebo - ho bonts'a Tirzepatide ha e thuse feela ho fokotsa boima ba 'mele empa hape e ntlafatsa metabolism ea tsoekere.
Tšireletseho le Mamello
Litla-morao tse atileng haholo li ne limala a mala, ho kenyeletsaho nyekeloa ke pelo, letšollo, le ho pipitleha, hangata e bonolo ebile e feta.
Sekhahla sa ho khaotsa ka lebaka la liketsahalo tse mpe e ne e batla e le4–7%.
Mafu a 'maloa a etsahetse nakong ea nyeoe, haholo-holo a amanang leCOVID 19, 'me li ne li sa amane ka ho toba le sethethefatsi sa thuto.
Ha ho liphapang tse kholo tse ileng tsa bonoa ka mathata a amanang le gallbladder.
Puisano
Phetoho ea mokhoa oa bophelo feela (lijo le boikoetliso) hangata li hlahisa feela~ 3% ho lahleheloa ke boima ba 'mele, joalo ka ha ho bonoa sehlopheng sa placebo.
Ka lehlakoreng le leng, Tirzepatide e ile ea thusa15-21% kakaretso ea ho fokotsa boima ba 'mele, e emelang aKa makhetlo a 5-7 phello e kholoanyane.
Ha ho bapisoa:
- Lithethefatsi tsa molomo tsa ho theola boima ba 'mele:hangata fumana 5-10% tahlehelo
- Opereishene ea Bariatric:e fihlella > 20% tahlehelo
Tirzepatide e koala lekhalo lipakeng tsa pharmacologic le mehato ea ho buoa - nyehelophokotso ea boima e matla, e sa senyeheng.
Habohlokoa, ho tšoenyeha ka ho mpefala ha metabolism ea glucose ha hoa bonoa. Ho fapana le hoo, Tirzepatide e ntlafalitse kutloisiso ea insulin le ho khutlisa prediabetes ho barupeluoa ba bangata.
Leha ho le joalo, teko ena e ile ea bapisa Tirzepatide le placebo - eseng ka kotloloho leSemaglutide.
Ho bapisa hlooho ho ea ho hlooho hoa hlokahala ho fumana hore na ke moemeli ofe ea hlahisang tahlehelo e kholo ea boima ba 'mele.
Qetello
Bakeng sa batho ba baholo ba nang le botenya kapa boima bo feteletseng le bo amanang le comorbidities, ho eketsahang-hang beke le beke Tirzepatidelenaneong le hlophisitsoeng la bophelo (lijo + boikoetliso) le ka lebisa ho:
- 15-21% ka karolelano ea ho fokotsa boima ba 'mele
- Lintlafatso tse kholo tsa metabolism
- Ho mamella le polokeho e phahameng
Ka hona, Tirzepatide e emela phekolo e sebetsang le e tiisitsoeng ea bongaka bakeng sa taolo ea boima bo tsitsitseng, e hlokometsoeng ke bongaka.
Nako ea poso: Oct-16-2025